Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna on August 1 and set a price target of $28.00. The company’s shares closed last Friday at $27.61. Take advantage of TipRanks Premium at ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA – Research Report) and MiMedx Group (MDXG – Research Report). Elevate Your Inve ...

One particular S&P 500 biotech continues to stink out our writer's Stocks and Shares ISA. Is it time he chucked in the towel? The post This S&P 500 stock could surge 55% in just 12 months, according ...

The Health and Human Services secretary said he is reviewing whether to remove the medical experts on the U.S. Preventive Services Task Force who advise on cancer screenings, HIV prevention drugs, and ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The Mpox outbreak has renewed interest in Kenya from various foreign vaccine suppliers. One of the few WHO-approved Mpox ...

The tide is turning in America’s COVID policy, with the recent announcement that the federal government will no longer recommend booster shots for most healthy Americans under the age of 65. This ...

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...